Analysts expect Cytek Biosciences, Inc. to report revenue of 197.59 M for 2026, against a range of 185.41 M to 209.76 M. The most recent reported year, 2025, came in at 201.49 M, a 4.7% beat against the 192.44 M consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 127.95 M | 164.04 M | 193.39 M | 200.45 M | 201.49 M | - | - | ||
| High Estimate | 124.57 M | 185.70 M | 210.01 M | 228.71 M | 211.17 M | 209.76 M | 232.82 M | ||
| Low Estimate | 108.99 M | 164.56 M | 186.72 M | 201.54 M | 173.71 M | 185.41 M | 201.99 M | ||
| Consensus Estimate | 116.78 M | 175.13 M | 198.36 M | 215.12 M | 192.44 M | 197.59 M | 217.40 M |
Analysts expect Cytek Biosciences, Inc. to report earnings per share of -0.32 for 2026, against a range of -0.34 to -0.30. The most recent reported year, 2025, came in at -0.52, a 271.4% miss against the -0.14 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.09 | 0.02 | 0.12 | 0.16 | -0.52 | - | - | ||
| High Estimate | 0.11 | 0.10 | -0.03 | 0.18 | -0.13 | -0.30 | -0.25 | ||
| Low Estimate | 0.11 | 0.08 | -0.03 | 0.14 | -0.15 | -0.34 | -0.29 | ||
| Consensus Estimate | 0.11 | 0.09 | -0.03 | 0.16 | -0.14 | -0.32 | -0.27 |